Preventing cGVHD involves careful donor selection and prophylactic immunosuppression. Techniques such as T-cell depletion in the graft and the use of post-transplant cyclophosphamide have shown promise in reducing the incidence of cGVHD. Early intervention and close monitoring post-transplant are essential to manage emerging symptoms effectively.
